Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276866 | 0.86 | DPP4 (0.58) | SLC6A2SLC6A4TACR1TSHROPRM1 | |
| Hydrochloric Acid SCHEMBL8651026 | 0.83 | OPRM1 (0.49) | SLC6A2SLC6A4TACR1CYP1A2CYP3A4 | |
| SCHEMBL30085024 | 0.82 | CYP1A2 (0.42) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5096867 | 0.82 | RPS6KB1 (0.52) | SLC6A2SLC6A4TACR1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8665660 | 0.81 | OPRM1 (0.48) | SLC6A2SLC6A4TACR1CYP1A2CYP3A4 | |
| SCHEMBL5110841 | 0.81 | RPS6KB1 (0.51) | SLC6A2SLC6A4TACR1CYP1A2CYP3A4 | |
| SCHEMBL16461973 | 0.80 | RPS6KB1 (0.50) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL468998 | 0.79 | CYP1A2 (0.62) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15017817 | 0.79 | CYP1A2 (0.62) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14438339 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4TACR1SLC6A3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | SLC6A2 1134/4885SLC6A4 458/4885TACR1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.